Hansa Biopharma AB: Hansa Biopharma announces reimbursement in the Netherlands of Idefirix[] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients https://investors.hansabiopharma.com/English/press-releases/press-releases-details/2021/Hansa-Biopharma-announces-reimbursement-in-the-Netherlands-of-Idefirix-imlifidase-as-desensitization-treatment-for-highly-sensitized-kidney-transplant-patients/default.aspx

]]>https://dev.proinvestor.com/forum/topic/442925/hansa-biopharma-announces-reimbursement-in-the-netherlandsRSS for NodeSun, 05 Jul 2026 04:17:40 GMTMon, 02 Aug 2021 04:06:50 GMT60